Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to ...

China’s Junshi Biosciences yesterday revealed that its wholly-owned subsidiary TopAlliance Bioscience has entered into a ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Under the agreement, LEO Pharma will be responsible for toripalimab's distribution, promotion, sales, etc., in up to 32 ...

Shanghai-based Junshi Biosciences has announced a partnership with Denmark’s LEO Pharma to distribute and commercialise the ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...

Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to distribute and market the monoclonal antibody, toripalimab, in Europe.

Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead ...

Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...